ARGX vs. TAK: argenx vs. Takeda Pharmaceutical Stock Comparison

Company Profile

argenx (ARGX) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while TAK is classified in Pharmaceuticals.

Both argenx (ARGX) and Takeda Pharmaceutical (TAK) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. argenx (ARGX) has a non-negative beta of 0.45.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Takeda Pharmaceutical (TAK) earns 0.56% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.

argenx (ARGX) at 31.73% converts revenue to bottom-line profit above its industry’s benchmark range, while Takeda Pharmaceutical (TAK) at 0.87% keeps roughly the typical share for its industry.

Both argenx (ARGX) at 36.27% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Takeda Pharmaceutical (TAK) at -1.66% is in the bottom quartile, showing a clear gap in revenue momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while argenx (ARGX) at 53.13% is closer to the peer norm — faster per-share earnings growth for TAK.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Takeda Pharmaceutical (TAK) shows current ratio of 1.15 against its industry benchmark, while argenx (ARGX) has no reading this period.

argenx (ARGX) at 0.01 keeps leverage in the lower quartile, while Takeda Pharmaceutical (TAK) at 0.72 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

argenx (ARGX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; argenx (ARGX) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

argenx (ARGX) at 32.12 is near its industry’s usual P/E ratio, while Takeda Pharmaceutical (TAK) at 300.29 sits above its peer range — an unusually expensive price for TAK’s trailing earnings.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while argenx (ARGX) at 9.86 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile relative to book while argenx (ARGX) at 172.23 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics